NCT07565129 PrevED MR. Improving Emotion Dysregulation Through Mixed Reality Based Dialectical Behavioral Therapy in Adolescents and Young Adults at Risk of Developing Eating Disorders.
| NCT ID | NCT07565129 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Universitat Internacional de Catalunya |
| Condition | Eating Disorders |
| Study Type | INTERVENTIONAL |
| Enrollment | 72 participants |
| Start Date | 2026-04-28 |
| Primary Completion | 2027-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 72 participants in total. It began in 2026-04-28 with a primary completion date of 2027-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to evaluate the feasibility and preliminary effects of PrevED MR, a group-based preventive intervention for adolescents and young adults at risk of developing eating disorders. PrevED MR is based on dialectical behavior therapy skills and uses mixed reality and virtual reality activities to support emotion regulation, mindfulness, distress tolerance, and body-related acceptance. Participants will be randomly assigned to either the PrevED MR intervention group or a waiting-list control group. The intervention will be delivered over 6 weeks, with two sessions per week, for a total of 12 sessions. Assessments will be conducted at baseline and after the intervention to examine changes in eating disorder symptoms, body image acceptance, emotion regulation strategies, rumination, usability, sense of presence, cybersickness, satisfaction, and adherence.
Eligibility Criteria
Inclusion Criteria: * Adolescents and young adults aged 13 to 35 years. * Spanish-speaking participants who are able to understand the study procedures and complete the assessment instruments. * Students recruited from participating schools, universities, or related recruitment settings. * Participants at mid-to-high risk of developing eating disorders, as assessed by the Eating Attitudes Test-26 (EAT-26) and selected subscales of the Eating Disorder Inventory-3 (EDI-3). * Participants who provide informed consent. For minors, informed consent from a parent or legal guardian will also be required, together with the minor's assent when applicable. Exclusion Criteria: * Current or past self-reported diagnosis of an eating disorder. * Current severe psychiatric symptoms or diagnosis that could interfere with participation, including suicidal, manic, or psychotic symptoms. * Severe neurodevelopmental disorder, intellectual disability, or other cognitive impairment that could interfere with understanding or completing the study procedures. * Physical, motor, or sensory impairment that could interfere with the assessment procedures or the use of the mixed/virtual reality intervention. * Current psychological or pharmacological treatment for a mental health disorder delivered on a weekly or biweekly basis. * Inability to understand Spanish. * Failure to provide informed consent. For minors, lack of parent or legal guardian consent will also be an exclusion criterion.
Contact & Investigator
Bruno Porras García, PhD
PRINCIPAL INVESTIGATOR
Universitat Internacional de Catalunya
Frequently Asked Questions
Who can join the NCT07565129 clinical trial?
This trial is open to participants of all sexes, aged 13 Years or older, up to 35 Years, studying Eating Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07565129 currently recruiting?
Yes, NCT07565129 is actively recruiting participants. Contact the research team at bporras@uic.es for enrollment information.
Where is the NCT07565129 trial being conducted?
This trial is being conducted at Barcelona, Spain.
Who is sponsoring the NCT07565129 clinical trial?
NCT07565129 is sponsored by Universitat Internacional de Catalunya. The principal investigator is Bruno Porras García, PhD at Universitat Internacional de Catalunya. The trial plans to enroll 72 participants.